LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive
Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX:
NEVPF) today announced that the English version of the
Annual report for 2018 is now available on the company's
website www.neurovive.com.
This information is information that NeuroVive Pharmaceutical
AB (publ) is obliged to make public pursuant to the Securities
Markets Act. The information was submitted for publication, through
the agency of the contact person set out below, at 10:00 a.m. CET on 25 March
2019.
About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial
medicine, with one project in clinical phase I (KL1333) for genetic
mitochondrial diseases and one project in clinical phase II
development for the prevention of moderate to severe traumatic
brain injury (NeuroSTAT®). The R&D portfolio also consists of
projects for genetic mitochondrial disorders, NASH and cancer. The
company advances drugs for rare diseases through clinical
development into the market, with or without partners. For projects
for common indications the goal is out-licensing in the preclinical
phase. A subset of compounds under NeuroVive's NVP015 program has
been licenced to Fortify Therapeutics, a BridgeBio company, for
local treatment development of Leber's Hereditary Optic Neuropathy
(LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is
also traded on the OTCQX Best Market in the US (OTC:
NEVPF).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-publishes-2018-annual-report,c2771265
The following files are available for download:
|
https://mb.cision.com/Main/6574/2771265/1012942.pdf
|
NeuroVive
Pharmaceutical AB publishes 2018 Annual report
|
For more information please contact:
Catharina Johansson
CFO
IR & Communications
+46 (0)46-275-62-21
ir@neurovive.com
NeuroVive Pharmaceutical AB (publ)
Medicon
Village
SE-223 81 Lund, Sweden
Tel: +46 (0)46-275-62-20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please
visit http://www.neurovive.com/press-releases/subscription-page/
Follow us on LinkedIn
View original
content:http://www.prnewswire.com/news-releases/neurovive-pharmaceutical-ab-publishes-2018-annual-report-300817564.html
SOURCE NeuroVive Pharmaceutical
